Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 19/20 | 0.81 |
| ▸ | CTSS | P25774 | 16/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.59 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593711 | 0.89 | CTSL (1.00) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL3600553 | 0.85 | CTSL (0.81) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL3604323 | 0.75 | CTSL (1.00) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL3588781 | 0.70 | CTSL (0.65) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL3594594 | 0.68 | CTSL (0.56) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL5569636 | 0.65 | CTSS (0.85) | CTSLCTSSCTSK | |
| SCHEMBL3601032 | 0.64 | CTSL (0.63) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL5568564 | 0.63 | CTSL (0.58) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL11448915 | 0.60 | SLC2A1 (0.58) | KCNH2 | |
| SCHEMBL5572278 | 0.60 | CTSL (0.72) | CTSLCTSSKCNH2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | CTSL 9/4885CTSS 1/4885KCNH2 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.